Co-Diagnostics, Inc. (CODX)
| Market Cap | 3.14M -93.5% |
| Revenue (ttm) | 721,386 -28.1% |
| Net Income | -47.06M |
| EPS | -19.36 |
| Shares Out | 7.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 529,148 |
| Open | 0.4486 |
| Previous Close | 0.4413 |
| Day's Range | 0.3926 - 0.4500 |
| 52-Week Range | 0.3926 - 16.3290 |
| Beta | 2.90 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About CODX
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In... [Read more]
Financial Performance
In 2025, Co-Diagnostics's revenue was $622,489, a decrease of -84.10% compared to the previous year's $3.92 million. Losses were -$46.90 million, 24.6% more than in 2024.
Financial StatementsNews
Co-Diagnostics JV’s Saragene biopsy test shows efficacy in published study
Co-Diagnostics (CODX) announced the publication of a peer-reviewed study using the Saragene Human Papillomavirus High Risk, or HPV-HR, Test manufactured by CoSara Diagnostics, the company’s joint vent...
Co-Diagnostics Announces Third Quarter 2026 Earnings Release Date and Webcast
SALT LAKE CITY, Oct. 29, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of mo...
Co-Diagnostics' Joint Venture CoSara Diagnostics Announces Publication of Peer-Reviewed HPV Screening Study Using CoSara's SARAGENE® Test
Follow-Up Biopsies Identified High-Grade Lesions or Cervical Cancer in 12 of 20 HPV-Positive Women, Including a Cohort with Predominantly Negative Cytology Results CoSara to Exhibit at MICROCON 2026, ...
Co-Diagnostics JV completes study of CoSara PCR MTB test, submits for clearance
Co-Diagnostics (CODX) announced that CoSara Diagnostics Pvt, the company’s joint venture in India, has completed its clinical performance study of the CoSara PCR Mycobacterium tuberculosis test on the...
Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India
CDSCO Clearance and Commercial Launch in India Anticipated Before Year-End 2026 Study Demonstrated 97.3% Sensitivity and 96.0% Specificity Consistent Performance Across Three Test Batches Integrated M...
Co-Diagnostics Proxy statement: Proxy filing
Co-Diagnostics filed a proxy statement on October 26, 2026, providing details for shareholder voting and corporate governance matters.
Co-Diagnostics' Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
Participation in NUWATIN 2026 to Support Advancement of Strategic Manufacturing, Technology Transfer, and Industrial Localization Initiatives Under Saudi Vision 2030 Invitation Follows Execution of Ma...
Co-Diagnostics Proxy statement: Proxy filing
Co-Diagnostics filed a proxy statement on October 16, 2026, providing details for shareholder voting and corporate governance matters.
Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Detection
Existing Sputum Sample-Preparation Technology Provides Potential Foundation for Plague Diagnostics Draws on Rapid-Response Experience with COVID-19, Mpox and Ebola Supported by Expanded Manufacturing ...
Co-Diagnostics to install Vector Smart laboratory for Native American tribe
Co-Diagnostics (CODX) has received an order from the Ute Indian Tribe Mosquito Abatement Department for a full Vector Smart mosquito surveillance laboratory installation. The order represents the comp...
Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
Ute Indian Tribe Mosquito Abatement Department to bring PCR-based mosquito surveillance testing in house SALT LAKE CITY, Oct. 8, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "t...
Co-Diagnostics Highlights Vector Smart® Momentum Following New Federal Initiative on Vector-Borne Disease
New Executive Order prioritizes improved detection and calls for federal R&D programs for rapid diagnostics for mosquito- and tick-borne diseases Company to participate in October 9 Utah Global Health...
Co-Diagnostics to Showcase Co-Dx PCR Platform* and MTB Test at WHX Labs Johannesburg, Highlight Ebola Assay Development
Ebola Assay in Development for Decentralized Testing on the Co-Dx PCR Platform SALT LAKE CITY, Oct. 6, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular ...
Co-Diagnostics to Participate in Global Health Events During UN General Assembly Week
Events Bring Together Global Health Leaders to Examine Tuberculosis and Preparedness for the Next Respiratory Pandemic SALT LAKE CITY, Sept. 23, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX...
Co-Diagnostics to Participate in Global Health Roundtable on Ebola and Outbreak Innovation
Roundtable discussion, taking place in New York City, will examine the ongoing Ebola outbreak and technologies needed to strengthen future outbreak response. Co-Dx will join officials from the U.S. De...
Co-Diagnostics Proxy statement: Proxy filing
Co-Diagnostics filed a proxy statement on September 21, 2026, providing details for shareholder voting and corporate governance matters.
Co-Diagnostics to Participate in Joint WHO/Unitaid/UNAIDS Annual Consultation Meeting on September 17-18, 2026
SALT LAKE CITY, Sept. 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of m...
Co-Diagnostics Transcript: Status update
A new collaboration with ReadyGo Diagnostics aims to enable blood-based molecular testing, expanding the platform's reach to blood-borne pathogens and underserved regions. Automation has doubled cartridge production efficiency, supporting scalable manufacturing in India and beyond. Clinical studies for decentralized tuberculosis testing are nearing completion, with regulatory submissions planned.
Co-Diagnostics Slides: Status update
Co-Diagnostics has posted slides in relation to its latest quarterly earnings report, which was published on September 16, 2026.
Co-Diagnostics and ReadyGo Diagnostics announce collaboration program
Co-Diagnostics (CODX) and ReadyGo Diagnostics, a UK-based developer of field sample-preparation technology, announced that the companies are collaborating to evaluate the potential use of ReadyGo’s sa...
Co-Diagnostics and ReadyGo Collaborate to Evaluate Blood-Based Molecular Testing at the Point of Need, Starting with Ebola
Blood-based testing could open new markets for the Co-Dx® PCR platform, including HIV and hepatitis B and C Co-Diagnostics and ReadyGo target decentralized Ebola detection as the first application of ...
Co-Diagnostics to hold a press conference
CEO Dwight Egan to hold a press conference in New York on September 16 at 10:30 am.Webcast Link
Co-Diagnostics to hold press conference on September 16
Co-Diagnostics (CODX) announced that it will host a press conference and live webcast Wednesday, September 16, at 10:30 a.m. Eastern Time. Co-Diagnostics CEO Dwight Egan will deliver a presentation fo...
Co-Diagnostics to Hold Press Conference
Media, analysts and investors are welcome to attend in person or via live webcast, Sept. 16 at 10:30 a.m.
Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida
Two full laboratory installations completed in Florida; installation and customer training underway in Indiana State surveillance has recorded 73 locally acquired dengue cases and identifies 14 dengue...